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descence. None of the treated patients had CDV-related nephro-
toxicity, although one patient had severe renal impairment prior to
CDV therapy (Table1). CDV is a safe and effective therapy for
adenoviral disease in pediatric oncology and BMT patients. We
present a novel algorithm that identiﬁed patients at high-risk for
severe adenoviral disease who would beneﬁt from CDV therapy. In
addition to GVHD, we propose HUS may be associated with
severe adenoviral disease in this popuation.
Table 1.
Risk
Cidofovir
Therapy n
Adenovirus
Clearance N (%)
Adenoviral-
Related
Mortality
N(%)/RR
Overall
Mortality
N(%)
HIGH
14(70%)
Treated 9 8 (89%) 1 (11%)
0.14
3 (33%)
Untreated 5 1 (20%) 4 (80%) 1 5 (100%)
LOW 6
(30%)
Treated 0 N/A N/A N/A
Untreated 6 6 (100%) 1
recrudescence
1 (17%) 1 (17%)
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Introduction: Little is known about post-mortem (PM) char-
acteristics in blood and marrow transplantation (BMT), includ-
ing the variables that predict the decision to perform the PM,
and whether meaningful information is obtained from the PM.
We performed a comprehensive analysis of PMs performed at
our center in order to determine PM rates, temporal trends, and
the utility of this investigation. Methods: All deceased patients
since the BMT program inception in 1990 until 2004 were
analyzed by computerized database and chart review. Patients
(pts) undergoing PM were compared to non-PM deceased pts.
PM reports were graded as to whether they showed major,
minor, or no disagreement with the ante-mortem diagnoses. PM
rates were compared to those of the general hospital population.
Results: Of the 476 pts undergoing myeloablative BMT, 225
died and 48 (27%) underwent PM, of which 41(85%) were full
and 7(15%) limited. The 48 PM pts had a median age of 44 years
(range) (18–63) and only 11 (23%) were post autologous BMT.
Forty-four PM pts (92%) died either on the transplant ward or
the ICU. The performance of a PM was more likely in pts dying
100 days post BMT (P  .001), with acute GVHD (P  .03),
in the ICU (P  .001), and after allografting (P  .001). PM
rates declined signiﬁcantly between the periods 1990–1994,
1995–1999, and 2000–2004 (P  .001). PM was more likely if
death occurred outside of ofﬁce hours (P  .02). The PM rate
at the general hospital was 21%, and showed a similar downward
temporal trend. Major, minor, and no disagreements at PM
were present in 22 (46%), 8(17%), and 18 (37%) of cases.
Conclusions: Despite 46% major disagreement between ante-
and postmortem diagnoses, rates for this procedure are falling in
concert with an overall reduction of PM in hospitalized pts.
Deaths occuring after 100 days post BMT and those outside of
a high care setting are less likely to undergo PM. As BMT pts
remain complex and liable to an extensive array of treatment and
disease-related complications, it is recommended that the PM
regains its role as a valuable investigation. This is especially
relevant in era of older and more inﬁrm pts undergoing non-
myeloablative BMT.
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Background: CMV infection can cause life-threatening compli-
cations in allogeneic stem cell transplant patients. Preemptive
treatment with ganciclovir is effective for patients with CMV
infection following ASCT. Valganciclovir is a valine esther of
ganciclovir with improved bioavailability. Methods: A retrospec-
tive analysis of ASCT patients receiving preemptive therapy with
ganciclovir or valganciclovir for treatment of CMV infection.
CMV infection was deﬁned as a titer of greater than 5 pg/ul using
the digene hybrid capture CMV-DNA assay. Results: A total of
144 patients received ASCT between January of 2001 and Septem-
ber of 2005. Of these, 39 received preemptive treatment with
valganciclovir (21), ganciclovir (13), or a combination of both
drugs (5). A total of 13 patients received preemptive therapy with
ganciclovir. All 13 patients were seropositive for CMV. Donor
source was: bone marrow (bm)  3, peripheral blood (pb)  10,
match unrelated donors (mud)  3, matched related sibling
(mrs)  10. Conditioning regimens included: reduced intensity
(rit)  5, ablative  8. Thirteen of thirteen patients were on
steroids for treatment of graft-versus-host disease (GVHD). Pa-
tients developed CMV infection on days 4 to 349 (median 
46) after ASCT. The peak CMV-DNA titer was 5.7 to 288 pg/ul
(median 48.65 pg/ul). Twelve of thirteen patients responded to
treatment. The time to response to treatment occurred 5 to 28 days
(median 13) after initiation of ganciclovir. One patient died from
interstitial pneumonitis related to CMV. Six patients received
maintenance therapy with valganciclovir and 3 patient developed
reactivation of their CMV viremia 69–84 days after their ﬁrst
infection.
A total 21 patients received preemptive treatment with valganci-
clovir. Donor source was pb  15, bm 6; mud  14, mrs  7 .
Nineteen patients were seropositive for CMV (2 seronegative pa-
tients with seropositive donor). Conditioning regimens included:
rit  6, ablative  15. Eighteen of twenty-one patients were on
steroids for treatment of GVHD. Patients developed CMV infec-
tion on days 11 to 700 (median  32 after ASCT). The peak
CMV-DNA titer was 2.1 to 149.3 pg/ul (median  26 pg/ul).
Twenty-one of twenty-one patients responded to preemptive ther-
apy with valganciclovir. The time to response to treatment oc-
curred 3 to 34 days (median  10) after initiation of valganciclovir.
Four patients developed CMV reactivation at 88–127 days after
the ﬁrst infection. Conclusions: Valganciclovir is comparable to
ganciclovir for the treatment of CMV infection.
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CMV prophylaxis with ganciclovir (Gan) post AlloSCT reduces
the incidence of CMV disease to 3%, but is associated with a
30% incidence of grade III/IV hematologic toxicity (Goodrich et al
NEJM. 1991). Foscarnet (Fos) is effective against CMV, but has
dose limiting renal toxicity (Deray et al Am J nephrol. 1989).
Combination Gan/Fos is more effective than monotherapy in
CMV retinitis in HIV patients (Peters et al J Inf Dis.1994). We
evaluated the safety and efﬁcacy of alternate day Gan (5 mg/kg/
48H)/Fos (90 mg/kg/48H) in 50 pediatric AlloSCT recipients
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